ReviewEmerging microbes & infections2018
Acinetobacter: an emerging pathogen with a versatile secretome.
Review in Emerging microbes & infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 67 citations in OpenAlex.
- Acinetobacter baumannii resistance trends in an ICU from Saudi Arabia over 12 years.The Indian journal of medical research · 2026Article
- Carbapenem-resistance in Acinetobacter baumannii: prevalence, antibiotic resistance profile and carbapenemase genes in clinical and hospital environmental strains.BMC infectious diseases · 2025Article
- Differences in gut microbiota composition, diversity, and predicted functional activity between wild and captive zoo Carollia perspicillata in a One Health perspective.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- The zinc metalloprotein MigC impacts cell wall biogenesis through interactions with an essential Mur ligase in Acinetobacter baumannii.PLoS pathogens · 2025Article
- Signaling inComputational and structural biotechnology journal · 2025Review
- The intricacies ofFrontiers in microbiology · 2025Review
- Pathogenicity and virulence ofVirulence · 2024Review
- Heterogeneity and Genomic Plasticity of Acinetobacter baumannii and Acinetobacter nosocomialis Isolates Recovered from Clinical Samples in India.Current microbiology · 2024Article
- Genomic epidemiology and resistant genes ofJournal of medical microbiology · 2024Article
- Structural characterization and functional insights into the type II secretion system of the poly-extremophile Deinococcus radiodurans.The Journal of biological chemistry · 2024Article
- Antibacterial Activity and Proposed Mode of Action of Extracts from Selected Zimbabwean Medicinal Plants againstAdvances in pharmacological and pharmaceutical sciences · 2024Article
- The role of type VI secretion system genes in antibiotic resistance and virulence inFrontiers in cellular and infection microbiology · 2024Article
- Virulence Factors and Pathogenicity Mechanisms ofAntibiotics (Basel, Switzerland) · 2023Review
- Microbial hitchhikers harbouring antimicrobial-resistance genes in the riverine plastisphere.Microbiome · 2023Article
- Review
- Uncovering the Secretion Systems ofAntibiotics (Basel, Switzerland) · 2023Review
- Review
- Deciphering the virulence factors, regulation, and immune response toFrontiers in cellular and infection microbiology · 2023Review
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Investigation on the characteristics of gut microbiota in critically endangered blue-crowned laughingthrush (Garrulax courtoisi).Molecular genetics and genomics : MGG · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is a notorious pathogen that has emerged as a healthcare nightmare in recent years because it causes serious infections that are associated with high morbidity and mortality rates. Due to its exceptional ability to acquire resistance to almost all available antibiotics, A. baumannii is currently ranked as the first pathogen on the World Health Organization's priority list for the development of new antibiotics. The versatile range of effectors secreted by A. baumannii represents a large proportion of the virulence arsenal identified in this bacterium to date. Thus, these factors, together with the secretory machinery responsible for their extrusion into the extracellular milieu, are key targets for novel therapeutics that are greatly needed to combat this deadly pathogen. In this review, we provide a comprehensive, up-to-date overview of the organization and regulatory aspects of the Acinetobacter secretion systems, with a special emphasis on their versatile substrates that could be targeted to fight the deadly infections caused by this elusive pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.